



HA

Director \$15

2094/65504-A/JPW/JHB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Shlomit Gilad, et al.  
U.S. Serial No.: 09/810,993  
Filed : March 16, 2001  
For : ATM MUTATIONS IN BREAST CANCER

#5/a  
pg  
3502

1185 Avenue of the Americas  
New York, New York 10036  
September 14, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**AMENDMENT IN RESPONSE TO NOTICE TO FILE  
MISSING PARTS OF APPLICATION UNDER 37 C.F.R. §1.53 (f)  
AND PETITION FOR A TWO-MONTH EXTENSION OF TIME**

In response to a Notice to File Missing Parts of Application under 37 C.F.R. §1.53(f) issued in connection with the above-identified application on May 24, 2001, a copy of which is enclosed as **Exhibit A**, applicants submit as **Exhibit B** a Declaration and Power of Attorney pursuant to 37 C.F.R. §1.53(f) and in compliance with 37 C.F.R. §1.63. The Declaration refers to the application's above-identified serial number and filing date. In accordance with the Notice, the deadline for submitting the Declaration and Power of Attorney was originally July 24, 2001. Applicants hereby request a two-month extension of time to respond to the May 24, 2001 Notice. The fee for a two-month extension of time for a small entity is ONE HUNDRED NINETY FIVE (\$195.00). A check which includes this amount is enclosed. Therefore, a response to the May 24, 2001 Notice is now due September 24, 2001. Accordingly, this Amendment is being timely filed.

09/19/2001 AWONDAF1 00000011 09810993

02 FC:216

195.00 OP

Applicants: Shlomit Gilad, et al.  
U.S. Serial No.: 09/810,993  
Filed: March 16, 2001  
Page 2



The enclosed check for TWO HUNDRED SIXTY DOLLARS (\$260.00) covers the surcharge for a small entity under 37 C.F.R. \$1.16(e) for submitting the enclosed Declaration.

Please amend the subject application as follows:

**In the specification:**

Please amend the specification as follows. Clean versions of the paragraphs as amended are set forth below:

Page 11, lines 18-19:

*A<sup>1</sup>* **Table 1 - Primers used in the study**  
(SEQ ID NOS: 2-29, respectively)

Page 14, lines 19-20:

*A<sup>2</sup>* **Table 2b. List of the primer sequences**  
(SEQ ID NOS: 30-45, respectively)

**REMARKS**

The specification has been amended to include sequence number identifiers as required. Applicants maintain that the amendments to the specification present no issue of new matter and are fully supported by the specification. The amendments to the specification to include the appropriate sequence identifiers (SEQ ID NOS.) are made to bring the specification of the subject application into compliance with 37 C.F.R. §§1.821 through 1.825. Pursuant to 37 C.F.R. \$1.121, an annotated version of the amended paragraphs of the specification relative to the previous version of those paragraphs are attached hereto as **Exhibit C**.



Applicants: Shlomit Gilad, et al.  
U.S. Serial No.: 09/810,993  
Filed: March 16, 2001  
Page 3


Applicants submit herewith sixteen (16) pages of Sequence Listing attached hereto as **Exhibit D** in compliance with the requirements of 37 C.F.R. §1.824. In addition, applicants submit herewith a computer readable copy of the Sequence Listing on the enclosed computer diskette, which has the same content as the paper copy attached as **Exhibit D**. Applicants submit as **Exhibit E**, a Statement in Accordance with 37 C.F.R. §1.821(f) certifying that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information which is submitted herewith as **Exhibit D** entitled "Sequence Listing".

If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

No fee, other than the enclosed \$260.00, is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
 John P. White Reg. No. 28,678	 Date

  
John P. White  
Registration No. 28,678  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400